A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer

Tongji Hospital

Status: Active, not recruiting

Conditions: Biomarker; Ovarian Cancer

Treatments: Genetic: Sequencing of DNA, RNA, and Proteins

Study type: Observational

Funder types: Other

Identifiers

NCT06483425

2024-TJ-OCBiomarker

Details and patient eligibility

About

This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.

Enrollment: 2,000 estimated patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with ovarian cancer.
• Willingness to undergo biomarker testing.
• Ability to provide informed consent for participation in the study.

Exclusion criteria

• Inability to comply with study requirements or follow-up visits.
• Previous participation in a conflicting clinical trial.

Trial design

2,000 participants in 1 patient group

Ovarian cancer pateitns

Description:

Patients diagnosed with Ovarian cancer in Tongji Hospital, Wuhan.

Treatment:

Genetic: Sequencing of DNA, RNA, and Proteins